OPKO Health (NASDAQ:OPK) Sets New 12-Month Low – Should You Sell?

OPKO Health, Inc. (NASDAQ:OPK)’s stock price reached a new 52-week low on Friday . The stock traded as low as $1.11 and last traded at $1.1150, with a volume of 1866323 shares trading hands. The stock had previously closed at $1.17.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on OPK. JPMorgan Chase & Co. started coverage on shares of OPKO Health in a report on Thursday, November 20th. They set a “neutral” rating on the stock. Barrington Research lowered their target price on shares of OPKO Health from $2.25 to $1.50 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, January 22nd. Finally, Wall Street Zen cut OPKO Health from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $2.03.

OPKO Health Trading Down 4.3%

The company has a debt-to-equity ratio of 0.26, a current ratio of 3.97 and a quick ratio of 3.52. The firm has a market capitalization of $850.16 million, a PE ratio of -3.73 and a beta of 1.50. The company’s fifty day simple moving average is $1.24 and its 200-day simple moving average is $1.34.

OPKO Health (NASDAQ:OPK) last released its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. OPKO Health had a negative net margin of 37.19% and a negative return on equity of 17.42%. The business had revenue of $148.50 million during the quarter, compared to analysts’ expectations of $139.76 million. During the same quarter in the previous year, the company earned $0.01 earnings per share. The company’s quarterly revenue was down 19.1% on a year-over-year basis. As a group, sell-side analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OPKO Health

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in OPKO Health by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 11,061,318 shares of the biotechnology company’s stock worth $13,940,000 after buying an additional 67,973 shares in the last quarter. Millennium Management LLC grew its holdings in OPKO Health by 39.2% in the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after buying an additional 1,798,385 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in OPKO Health by 150.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock valued at $7,544,000 after buying an additional 3,600,378 shares in the last quarter. UBS Group AG increased its stake in shares of OPKO Health by 12.1% in the 4th quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company’s stock worth $6,745,000 after acquiring an additional 577,248 shares during the last quarter. Finally, AWM Investment Company Inc. increased its stake in shares of OPKO Health by 8.1% in the 2nd quarter. AWM Investment Company Inc. now owns 2,000,000 shares of the biotechnology company’s stock worth $2,640,000 after acquiring an additional 150,000 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.